Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities ...

Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.

Intuit Inc. , the global financial technology platform that makes TurboTax, Credit Karma, QuickBooks, and Mailchimp, will announce its second-quarter financial results for fiscal year 2025 on February ...

Neurocrine Biosciences, Inc. announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time ...

Using a single-cell sequencing technique, Brazilian researchers have created the first cell atlas of focal cortical dysplasia ...

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (NasdaqGS:MRNA) from Buy to ...

BTIG Research began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) in a research report issued on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a ...

Using a single-cell sequencing technique, Brazilian researchers have created the first cell atlas of focal cortical dysplasia (FCD), a malformation of the cerebral cortex that leads to drug-resistant ...

EXCLUSIVE. According to the Nobel Prize-winning economist, Europe needs to review its innovation policy, or it will disappear ...

Sen. Brandon Shippy, R-New Plymouth, is proposing to put a 10-year pause on certain types of vaccines that were used for some ...

Discover the top 3 undervalued Life Sciences Tools & Services stocks for Thursday, January 30 based on AAII’s Stock Grades.